-
Imiglucerase is a
medication used in the
treatment of Gaucher's disease. It is a
recombinant DNA-produced
analogue of the
human enzyme β-glucocerebrosidase...
-
expensive to manufacture.
Available recombinant glucocerebrosidases are:
Imiglucerase (approved in 1995)
Velaglucerase (approved in 2010)
Taliglucerase alfa...
- and
expensive procedure. A new
version of Ceredase,
called Cerezyme,
Imiglucerase which Genzyme produced in 1994
using genetically modified cells in vitro...
- not
being fully committed to
developing a drug that
would compete with
imiglucerase (brand name Cerezyme), Genzyme's
flagship treatment for Gaucher's disease...
- harvesting, and are less
expensive to
manufacture (see
imiglucerase).
Deegan PB, Cox TM (2012). "
Imiglucerase in the
treatment of
Gaucher disease: a
history and...
-
Agalsidase beta IV
Fabry disease Agalsidase alfa IV
Gaucher disease Imiglucerase IV
Gaucher disease Taliglucerase alfa IV
Gaucher disease Velaglucerase...
-
synthesis of most glycosphingolipids.
Earlier treatments on the
market (
imiglucerase (approved in 1995),
velaglucerase (approved in 2010),
taliglucerase alfa...
-
gaucher disease.
Ceredase (Alglucerase), for Gaucher's disease.
Cerezyme (
Imiglucerase), for Gaucher's disease.
Elaprase (Idursulfase),
marketed by Shire. Epicel...
-
imidaprilat (INN)
imidazole salicylate (INN)
imidocarb (INN)
imidoline (INN)
imiglucerase (INN)
imiloxan (INN)
iminophenimide (INN)
imipenem (INN)
imipramine (INN)...
- manufacturing, marketing, and distribution.
Genzyme charged $3.50 a unit.
Imiglucerase was
granted orphan drug
status in the US, Australia, and ****an. By 1994...
